A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
GlaxoSmithKline
Summary
The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seeks to determine the clinical efficacy and pharmacokinetic (PK) properties of GSK5926371.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Has histologically confirmed Relapsed/Refractory (R/R) B-NHL, for which systemic treatment is indicated, 1. Has measurable disease, 2. Has received at least 2 prior lines of systemic anti-neoplastic therapy, including an anti-CD20-containing combination appropriate for the indication; 3. Has documented disease relapse, progression or disease refractory to the most recent line of therapy, per Lugano criteria.: * Willing to use adequate contraception (Participant of childbearing potential \[POCBP\] only). * Is capable of giving signed informed consent * Has an Easte…
Interventions
- DrugGSK5926371
GSK5926371 will be administered at different dose levels.
Locations (3)
- GSK Investigational SiteCanton, Ohio
- GSK Investigational SiteToronto, Ontario
- GSK Investigational SiteTokyo